Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Original Article

Self-testing strategy to eliminate hepatitis C as per World Health Organization’s goal: Analysis of disease burden and cost-effectiveness

Gyeongseon Shin, Beom Kyung Kim, SeungJin Bae, Hankil Lee, Sang Hoon Ahn

Clin Mol Hepatol. 2025;31(1):166-178. Published online October 4, 2024

DOI: https://doi.org/10.3350/cmh.2024.0484

View: 1353 Download: 122

Correspondence

Correspondence to editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”

Chang Hun Lee, In Hee Kim, Sook-Hyang Jeong

Clin Mol Hepatol. 2024;30(4):997-999. Published online July 29, 2024

DOI: https://doi.org/10.3350/cmh.2024.0588

View: 1161 Download: 40

Editorial

Elimination of viral hepatitis: How far are we?: Editorial on “Core indicators related to the elimination of hepatitis B and C virus infection in South Korea: A nationwide study”

Eun Ju Cho

Clin Mol Hepatol. 2024;30(4):663-664. Published online July 22, 2024

DOI: https://doi.org/10.3350/cmh.2024.0557

View: 1151 Download: 43 Web of Science: 1 Crossref: 1

Original Article

Scaling up the in-hospital hepatitis C virus care cascade in Taiwan

Chung-Feng Huang, Pey-Fang Wu, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Cheng-Ting Hsu, Po-Yao Hsu, Hung-Yin Liu, Ying-Chou Huang, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Chia-Yen Dai, Wan-Long Chuang, Ming-Lung Yu

Clin Mol Hepatol. 2021;27(1):136-143. Published online December 3, 2020

DOI: https://doi.org/10.3350/cmh.2020.0150

View: 7500 Download: 197 Web of Science: 33 Crossref: 34

Cost-effectiveness and return on investment of hepatitis C virus elimination in China: A modelling study

Meiyu Wu, Jing Ma, Xuehong Wang, Sini Li, Chongqing Tan, Ouyang Xie, Andong Li, Aaron G Lim, Xiaomin Wan

Received August 13, 2024 Accepted December 2, 2024

DOI: https://doi.org/10.3350/cmh.2024.0664 [Accepted]

View: 867 Download: 122

1 |

Viewed By 7180	MAFLD: How is it different from NAFLD?
Viewed By 6618	Epidemiology of metabolic dysfunction-associated steatotic liver disease
Viewed By 5464	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 5256	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4734	Role of noninvasive tests in the prognostication of metabolic dysfunction-associated steatotic liver disease

Cited By 298	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 269	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 181	MAFLD: How is it different from NAFLD?
Cited By 93	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 88	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search